Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer

Chemotherapy

Volumn 53, Issue 3, 2007, Pages 226-232

  Satoh, Seiji ^a   Kawashima, Kazuhiko ^a   Matsumoto, Shigemi ^a   Hasegawa, Suguru ^a   Okabe, Hiroshi ^a   Nomura, Akinari ^a   Yoshibayashi, Hiroshi ^a   Watanabe, Go ^a   Nagayama, Satoshi ^a   Fukushima, Masanori ^a   Sakai, Yoshiharu ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastric cancer; Outpatient chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; IRINOTECAN; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; GROUPS BY AGE; HOSPITALIZATION; HUMAN; INTESTINE; JAPAN; LEUKOPENIA; LOW DRUG DOSE; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; PIGMENTATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SOCIAL BEHAVIOR; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR;

EID: 34147212720     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100865     Document Type: Article

References (25)

1. Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29; 870-873.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36, 144.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
6. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
7. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212.
8. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group (in Japanese). Gan To Kagaku Ryoho 1994;21:1033-1038.
9. Enzinger P, Kulke M, Clark JL, Ryan D: Phase II trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach. ASCO, 2000, abstract 1234.
10. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF: Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-274.
11. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-419.
12. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-1317.
13. Wohrer SS, Raderer M, Hejna M: Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004;15:1585-1595.
14. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
15. Shimada S, Yagi Y, Kuramoto M, Aoki N, Ogawa M: Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep 2003;10:687-691.
16. Shimoyama S, Aoki F, Shimizu N, Tatsutomi Y, Mafune K, Kaminishi M: Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report. Int J Clin Oncol 2003;8:49-52.
17. Tadatomo H, Suzuki K, Ando M, Yamashita S, Tanaka K, Maruyama S, Harada Y, Ohnuma S, Sakaniwa N, Koyanagi Y: A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP (in Japanese). Gan To Kagaku Ryoho 2001;28:821-824.
18. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-3361.
19. Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer 1998;1:10-24.
20. Ikeguchi M, Matsumoto S, Yoshioka S, Murakami D, Kanaji S, Ohro S, Yamaguchi K, Saito H, Tatebe S, Kondo A, Tsujitani S, Kaibara N: Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer. Chemotherapy 2005;51:15-20.
21. Tsavaris N, Tentas K, Kosmidis P, Mylonakis N, Sakelaropoulos N, Kosmas C, Lisaios B, Soumilas A, Mandrekas D, Tsetis A, Klonaris C: A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 1996;42:220-226.
22. Funato T, Kozawa K, Fujimaki S, Miura T, Kaku M: Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Chemotherapy 2001;47:297-303.
23. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-323.
24. Persiani R, D'Ugo D, Rausei S, Sermoneta D, Barone C, Pozzo C, Ricci R, La Torre G, Picciocchi A: Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol 2005;89:227-236.
25. Park SH, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH: Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2006;57:91-96.